Medicare Price Negotiations: HHS Nominee Suggests Adapting Part D 'Learnings' To Part B
Executive Summary
Alex Azar talks about price negotiation in Medicare Part B, whether his biopharma industry ties would influence his decisions as head of HHS, insulin price increases and importation during the first of his confirmation hearings.
You may also be interested in...
HHS Secretary Azar Likely To Advance Medicare Drug Pricing Policies
Alex Azar's nomination clears Senate with support from five Democrats and one Independent – but not Rand Paul, R-Ky.
HHS Secretary Azar Likely To Advance Medicare Drug Pricing Policies
Alex Azar's nomination clears Senate with support from five Democrats and one Independent – but not Rand Paul, R-Ky.
List Price Increase 'Incentives' Must Be Reversed, HHS Nominee Azar Says
Senate Finance Committee Democrats grill HHS Secretary nominee Alex Azar about his ability to foster solutions to high drug pricing given his industry background, as well as his support for alternative financing in Medicaid.